Castle biosciences stock.

The estimated Net Worth of Mara G. Aspinall is at least $2.42 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,626,983 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.Nov 3, 2023 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new discovery data from an ongoing study exploring the potential for developing a complementary, minimally invasive test to evaluate small, suspicious lesions of uncertain malignant potential in patients’ eyes. Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically targeting …6 hours ago · Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma.

Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Mr. Harrison CSTL stock SEC Form 4 insiders trading. Miles has made over 2 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,825 units of CSTL stock worth $76,041 on 2 June 2023.. The largest trade he's ever made was exercising 3,825 units of Castle Biosciences …Mar 1, 2023 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago.

Dec 4, 2023 · Castle Biosciences Price Performance. NASDAQ CSTL traded up $0.07 during trading on Monday, reaching $20.04. The company’s stock had a trading volume of 33,667 shares, compared to its average ... Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago.

Castle Biosciences Inc. Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians …NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.51 -0.27 (-1.37%) As of 03:38PM EST. Market open. 1d 5d 1m 6m YTD 1y 5y Max Full screen …CSTL Castle Biosciences, Inc. Stock Price & Overview 2.63K followers $19.99 0.13 ( +0.65%) 4:00 PM 11/30/23 NASDAQ | $USD | Post-Market: $19.99 4:17 …How much is Castle Biosciences stock worth today? ( NASDAQ: CSTL) Castle Biosciences currently has 26,910,548 outstanding shares. With Castle Biosciences stock trading at $18.06 per share, the total value of Castle Biosciences stock (market capitalization) is $486.00M. Castle Biosciences stock was originally listed at a price of $21.40 in Jul ...

Castle Biosciences is a leading diagnostic company focused on transforming disease management by keeping people first…. The patients who benefit from the information that our advanced diagnostic tests provide. The clinicians who use our tests to guide disease management decisions. Our talented and valued employees. Our investors.

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to …

White Castle does not allow for the purchase of franchises. Each of the restaurants is privately owned and operated through the White Castle parent company. Because the company is privately owned, it doesn’t offer stock options to the publi...The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ...At Castle Biosciences, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of …Jun 2, 2023 · Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ... Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ...The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ...

Nov 16, 2023 · Nikkei 225. 33,424.41. -0.28%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Castle Biosciences Inc (CSTL.OQ) real-time stock quotes, news, price and financial information from ... On November 2, 2023, Castle Biosciences (NASDAQ:CSTL) released its Q3 2023 financial report, showcasing impressive results. The company reported a loss of $ (0.26) per share, surpassing the analyst consensus estimate of $ (0.76) by an impressive 65.79 percent. This marks a remarkable 66.23 percent increase in losses compared to the same period ...The 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical Laboratory Improvement …The estimated Net Worth of Mara G. Aspinall is at least $2.79 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,995,313 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.Dec 1, 2023 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients diagnosed with cutaneous melanoma. Castle Biosciences (CSTL-0.50%) stock was absolutely crushing it on Friday, with shares skyrocketing 54.4% as of 11:47 a.m. ET. The huge gain came after Novitas, a regional Medicare administrative ...

Shares of Castle Biosciences are trading down 1.98% over the last 24 hours, at $13.40 per share. A move to $30.00 would account for a 123.88% increase from the current share price. About Castle ...Castle Biosciences is registered under the ticker NASDAQ:CSTL . Their stock opened with $16.00 in its Jul 24, 2019 IPO. Castle Biosciences is funded by 11 investors. Spindletop Capital Management and BrightEdge Fund are the most recent investors. Castle Biosciences has acquired 3 organizations. Their most recent acquisition was AltheaDx …

Key Insights. Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their trading actions. 51% of the business is held by the top 12 shareholdersCastle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Call Transcript Cathie Wood's Top 15 Small-Cap Stock Picks Small Caps Begin to Rebound: 5 Stocks to Buy Now Castle Biosciences, Inc. (NASDAQ ...It’s estimated that there are over 30,000 castles in Ireland. Some are parts of ruins, some are homes, some are offices — and some castles in Ireland are available for people from all over the world to visit and stay in during their vacatio...In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...Castle Biosciences is registered under the ticker NASDAQ:CSTL . Their stock opened with $16.00 in its Jul 24, 2019 IPO. Castle Biosciences is funded by 11 investors. Spindletop Capital Management and BrightEdge Fund are the most recent investors. Castle Biosciences has acquired 3 organizations. Their most recent acquisition was AltheaDx …The bid-ask spread can indicate a stock’s liquidity, which is how easy it is to buy and sell in the marketplace. Often, a smaller spread suggests higher liquidity, meaning more buyers …Jul 24, 2023 · Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 15.45% so far this month. During the month of July, Castle Biosciences Inc’s stock price has reached a high of $20.96 and a low of $13.18. Over the last year, Castle Biosciences Inc has hit prices as high as $36.10 and as low as $9.26. Year to date ...

According to the issued ratings of 4 analysts in the last year, the consensus rating for Castle Biosciences stock is Buy based on the current 4 buy ratings for CSTL. The average twelve-month price prediction for Castle Biosciences is $32.29 with a high price target of $41.00 and a low price target of $25.00. Learn more on CSTL's analyst rating ...

Leadership: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Patents with Castle Biosciences. No other potential conflicts of interest were reported. OPTIONS & TOOLS. Export Citation: Track Citation: Add To Favorites: Rights & Permissions; COMPANION …

Castle Biosciences, Inc. (NASDAQ:NASDAQ:CSTL) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ETCompany ParticipantsCamilla Zuckero - Vice...You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Derek has made over 103 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 600 units of CSTL stock worth 12,060$ on 3 August 2023. 世界市場 道具 ポートフォリオ. Track performance, allocation, dividends, and risks ...Oct 15, 2023 · Castle Biosciences lost $2.58 a share on just over $137 million in sales in FY2022. Read why I rate CSTL stock as a hold. Castle Biosciences is a pioneer in this field of spatial biology. Our biologically aware AI platform delivered Tissue Cypher® to the clinic, the world’s first precision medicine test to predict the risk of developing esophageal cancer in Barrett’s Esophagus patients – one of the world’s deadliest cancers. Castle Biosciences continues to pursue deployment …Castle Biosciences Inc Stock Earnings The value each CSTL share was expected to gain vs. the value that each CSTL share actually gained. CSTL ( CSTL ) reported Q3 2023 earnings per share (EPS) of -$0.26 , beating estimates of -$0.76 by 66.32% .Are you yearning for adventure, breathtaking landscapes, and a journey through history? Look no further than a tour of Scotland and Ireland. These two countries boast rich cultural heritage, stunning natural beauty, and countless attraction...In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...Castle Biosciences is forecast to grow earnings and revenue by 32.8% and 14.8% per annum respectively. EPS is expected to grow by 32.1% per annum. Return on equity is forecast to be -26.8% in 3 years.

FRIENDSWOOD - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx-Melanoma and DecisionDx-UM will be shared during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6.Find real-time CSTL - Castle Biosciences Inc stock quotes, company profile, news and forecasts from CNN Business.By providing your email address below, you are providing consent to Castle Biosciences to send you the requested Investor Email Alert updates. * Required. Email Address*. Investor Alert Options*. News. Events & Presentations. Quarterly Reports. Annual Reports. SEC Filings.Castle Biosciences Inc (CSTL) Stock Expected to Experience Positive Growth on November 3, 2023: Analysts Predictions and Ratings. On November 3, 2023, Castle Biosciences Inc (CSTL) stock is expected to experience positive growth, according to analysts. The 8 analysts offering 12-month price forecasts for CSTL have a median …Instagram:https://instagram. is rocket mortgage a good companyjpmorgan equity premium income etf dividendvanguard tax managed capital appreciationlithium stock price today Europe PMC is an archive of life sciences journal literature.Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ... pfizer cancer drugswhat is the best dental insurance in florida If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...The estimated net worth of David S. Kabakoff is at least $3.83 million as of June 22nd, 2020. Mr. Kabakoff owns 212,178 shares of Castle Biosciences stock worth more than $3,831,935 as of November 6th. This net worth evaluation does not reflect any other investments that Mr. Kabakoff may own. Learn More about David S. Kabakoff's net … ultra high net worth individual Jul 7, 2023 · In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00. Below is ... The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $34.00 average price target, implying a 67.49% upside from current levels.Nov 17, 2023 · 4 Wall Street research analysts have issued 1-year price targets for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $41.00. On average, they anticipate the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 64.4% from the stock's current price.